These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 10417175)

  • 41. Immunogenicity of a five-component acellular pertussis vaccine in infants and young children.
    Halperin SA; Barreto L; Friesen B; Meekison W
    Arch Pediatr Adolesc Med; 1994 May; 148(5):495-502. PubMed ID: 7910089
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acquisition of IgG serum antibodies against two Bordetella antigens (filamentous hemagglutinin and pertactin) in children with no symptoms of pertussis.
    Isacson J; Trollfors B; Taranger J; Lagergård T
    Pediatr Infect Dis J; 1995 Jun; 14(6):517-21. PubMed ID: 7667057
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel method for evaluating natural and vaccine induced serological responses to Bordetella pertussis antigens.
    Berbers GA; van de Wetering MS; van Gageldonk PG; Schellekens JF; Versteegh FG; Teunis PF
    Vaccine; 2013 Aug; 31(36):3732-8. PubMed ID: 23742995
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pertussis immunization with acellular vaccines in Ghanaian children.
    Hori H; Afari A; Akanmori BD; Kamiya Y; Sakatoku H; Nkrumah FK; Kamiya H; Chazono M; Fukai K
    Ann Trop Paediatr; 1995 Jun; 15(2):141-6. PubMed ID: 7677415
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.
    Pichichero ME; Edwards KM; Anderson EL; Rennels MB; Englund JA; Yerg DE; Blackwelder WC; Jansen DL; Meade BD
    Pediatrics; 2000 Jan; 105(1):e11. PubMed ID: 10617748
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age.
    Halperin SA; Scheifele D; Barreto L; Pim C; Guasparini R; Medd L; Meekison W; Eastwood BJ
    Pediatr Infect Dis J; 1999 Sep; 18(9):772-9. PubMed ID: 10493336
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Laboratory investigation of immune responses to acellular pertussis vaccines when used for boosting adolescents after primary immunisation with whole cell pertussis vaccines: a comparison with data from clinical study.
    Reynolds E; Walker B; Xing D; Southern J; Asokanathan C; Dagg B; Corbel M; Miller E
    Vaccine; 2006 Apr; 24(16):3248-57. PubMed ID: 16480794
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differences of IgG antibody avidity after an acellular pertussis (aP) booster in adolescents after a whole cell (wcP) or aP primary vaccination.
    Prelog M; Almanzar G; Rieber N; Ottensmeier B; Zlamy M; Liese J
    Vaccine; 2013 Jan; 31(2):387-93. PubMed ID: 23142306
    [TBL] [Abstract][Full Text] [Related]  

  • 49. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
    Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity and safety of a monovalent, multicomponent acellular pertussis vaccine in 15 month-6-year-old German children. Monovalent Acellular Pertussis Vaccine Study Group.
    Stehr K; Heininger U; Uhlenbusch R; Angersbach P; Hackell J; Eckhardt T
    Eur J Pediatr; 1995 Mar; 154(3):209-14. PubMed ID: 7758519
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children.
    Podda A; Carapella De Luca E; Titone L; Casadei AM; Cascio A; Bartalini M; Volpini G; Peppoloni S; Marsili I; Nencioni L
    J Pediatr; 1993 Jul; 123(1):81-4. PubMed ID: 8320630
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunogenicity of a three-component acellular pertussis vaccine administered at birth.
    Belloni C; De Silvestri A; Tinelli C; Avanzini MA; Marconi M; Strano F; Rondini G; Chirico G
    Pediatrics; 2003 May; 111(5 Pt 1):1042-5. PubMed ID: 12728086
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cellular immunity as a potential cause of local reactions to booster vaccination with diphtheria and tetanus toxoids and acellular pertussis antigens.
    Scheifele DW; Ochnio JJ; Halperin SA
    Pediatr Infect Dis J; 2009 Nov; 28(11):985-9. PubMed ID: 19755930
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Pertussis Outer Membrane Vesicle-Based Vaccine Induces Lung-Resident Memory CD4 T Cells and Protection Against
    Zurita ME; Wilk MM; Carriquiriborde F; Bartel E; Moreno G; Misiak A; Mills KHG; Hozbor D
    Front Cell Infect Microbiol; 2019; 9():125. PubMed ID: 31106160
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines.
    Tozzi AE; Anemona A; Stefanelli P; Salmaso S; Ciofi degli Atti ML; Mastrantonio P; Giammanco A;
    Pediatrics; 2001 Feb; 107(2):E25. PubMed ID: 11158499
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum IgG, IgA, and IgM responses to pertussis toxin, filamentous hemagglutinin, and agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with whole-cell pertussis vaccine.
    Thomas MG; Ashworth LA; Miller E; Lambert HP
    J Infect Dis; 1989 Nov; 160(5):838-45. PubMed ID: 2572651
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cell-mediated immune response of healthy adults to Bordetella pertussis vaccine antigens.
    Ausiello CM; Lande R; la Sala A; Urbani F; Cassone A
    J Infect Dis; 1998 Aug; 178(2):466-70. PubMed ID: 9697728
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Responses to acellular pertussis vaccines and component antigens in a coughing-rat model of pertussis.
    Hall E; Parton R; Wardlaw AC
    Vaccine; 1998 Oct; 16(17):1595-603. PubMed ID: 9713934
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
    Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
    Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An acellular pertussis vaccine in healthy adults: safety and immunogenicity. Pennridge Pediatric Associates.
    Rothstein EP; Anderson EL; Decker MD; Poland GA; Reisinger KS; Blatter MM; Jacobson RM; Mink CA; Gennevois D; Izu AE; Sinangil F; Langenberg AG
    Vaccine; 1999 Aug; 17(23-24):2999-3006. PubMed ID: 10462235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.